This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Santarus Reports Third Quarter 2013 Financial Results

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the quarter and nine months ended September 30, 2013. Key financial results include:
  • Total revenues of $98.8 million grew 81% compared with $54.7 million for the third quarter of 2012
  • Net income of $30.3 million, or $0.38 diluted earnings per share (EPS), compared with $9.0 million, or $0.13 diluted EPS for the third quarter of 2012
  • Non-GAAP adjusted earnings were $35.6 million and diluted non-GAAP adjusted EPS were $0.45 in the third quarter of 2013 compared with non-GAAP adjusted earnings of $12.3 million and diluted non-GAAP adjusted EPS of $0.18 for the third quarter of 2012
  • Cash, cash equivalents and short-term investments were $168.7 million as of September 30, 2013, an increase of approximately $74.0 million compared with $94.7 million at December 31, 2012

Santarus Conference Call Cancelled

The previously scheduled Santarus investor conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) today, November 7, 2013 has been cancelled as a result of the joint press release issued today after market close by Santarus and Salix Pharmaceuticals, Ltd. announcing that their Boards of Directors have unanimously approved a definitive merger agreement under which Salix will acquire Santarus through a tender offer followed by a merger for $32.00 in cash for a purchase price of approximately $2.6 billion.

Salix will host a conference call at 4:30 p.m. Eastern Time today, Thursday, November 7, 2013. Interested parties can access the conference call by way of webcast or telephone. The live webcast will be available at A replay of the webcast will be available at the same location. The telephone numbers to access the live conference call are (800) 319-9003 (U.S. and Canada) or (719) 325-2134 (international). The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international). The access code for the call is 612126.

Third Quarter 2013 Financial Results

Total revenues increased to $98.8 million for the third quarter of 2013, compared with $54.7 million for the third quarter of 2012 as indicated below ($ in millions):
  Three Months Ended   Increase
September 30, (Decrease)
  2013     2012
Product sales, net
GLUMETZA $ 45.6 $ 39.3 $ 6.3
ZEGERID 27.1 8.4 18.7
UCERIS 19.6 - 19.6
CYCLOSET 4.2 4.3 (0.1 )
FENOGLIDE   1.6   1.7   (0.1 )
Total product sales, net 98.1 53.7 44.4
Other revenue   0.7   1.0   (0.3 )
Total revenues $ 98.8 $ 54.7 $ 44.1

Net income for the third quarter of 2013 was $30.3 million and diluted EPS was $0.38. Non-GAAP adjusted earnings for the third quarter of 2013 were $35.6 million and diluted non-GAAP adjusted EPS were $0.45. In the third quarter of 2012 the company reported net income of $9.0 million, diluted EPS of $0.13 and non-GAAP adjusted earnings of $12.3 million, and had diluted non-GAAP adjusted EPS of $0.18.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs